ESR1 and neoplasm: Mutated TP53, detected either by immunohistochemistry or by sequencing, has been reported to associate strongly with aggressive tumor phenotypes, e.g. estrogen receptor negativity and high grade, and poor breast cancer survival [2, 7, 8, 10, 11, 14].